<DOC>
	<DOCNO>NCT00481182</DOCNO>
	<brief_summary>To assess combined effect fosamprenavir 700mg BID + ritonavir 100mg BID + standardize dose methadone , plasma total unbound methadone enantiomer pharmacokinetics ( PK ) , opiate pharmacodynamic ( PD ) measure , safety . The effect methadone plasma amprenavir PK also assess comparison historical control data .</brief_summary>
	<brief_title>Co-Administration Of Fosamprenavir With Methadone : A Drug Interaction Study .</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<criteria>Subject enrol certify methadone maintenance program least 12 week prior Period 1 , Day 1 . Subject receive methadone = 200mg QD remain unchanged 30 day The subject male , female age 18 64 year age . A female eligible enter participate nonchildbearing potential childbearing potential . If childbearing potential , female must negative serum pregnancy test Screening , agree one following : Complete abstinence sexual intercourse 2 week prior administration study drug . Sexual intercourse vasectomized partner . Body mass index 19.00 32.00 kg/m2 . Willing refrain use illicit drug adhere protocolstated restriction participate study . Able understand comply protocol requirement instruction likely complete study plan . Able give write informed consent prior screen . Subject clinically significant abnormality identify screen medical laboratory evaluation , include 12lead ECG . Subject preexist condition could interfere absorption , metabolism , and/or excretion study drug . Subject currently history decompensated liver disease ( i.e. , ascites , esophageal rectal varix , hepatic encephalopathy ) current evidence active hepatitis ( AST ALT &gt; 2.5x ULN ) . Subject evidence liver impairment screening ( i.e. , INR &gt; 1.7 , total bilirubin &gt; 2.0 mg/dL , albumin &lt; 3.5 g/dL ) . Subject inadequate venous access . Subject history hypersensitivity reaction component FPV , APV , RTV , drug chemically related FPV , APV , RTV .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>PK</keyword>
	<keyword>PD</keyword>
	<keyword>FPV</keyword>
	<keyword>RTV</keyword>
	<keyword>APV</keyword>
	<keyword>ritonavir</keyword>
	<keyword>fosamprenavir</keyword>
	<keyword>amprenavir</keyword>
	<keyword>methadone</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
</DOC>